BioSpace News Archive

Editas Medicine, Inc., a leading genome editing company, announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity.

Microbot Medical Inc. has concluded 2020 with the achievement of several operating and developmental milestones.

IDE397 is being developed as a potential best-in-class MAT2A inhibitor for MTAP-deletion, which is prevalent in approximately 15% of all solid tumors

Seasoned sales veteran from Medtronic tasked to build and lead U.S. commercialization infrastructure as CytoSorbents sells CytoSorb under U.S. FDA Emergency Use Authorization for COVID-19 and leverages FDA Breakthrough Designation for potential future U.S. approval.

SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, announced it has appointed Rick Barnett and Dr. Allan J. Collins to its board of directors, effective January 8, 2021.

Calyx, a leading provider of Medical Imaging, eClinical, and Regulatory solutions and services to solve complex challenges in clinical research, launched as an independent company following the strategic separation of the Parexel Informatics business from Parexel International.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, outlined significant clinical milestones for 2021 and provided an overview of recent progress.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern.

Investigational New Drug Applications (IND) submitted for PBFT02 for Frontotemporal Dementia with Granulin Mutation (FTD-GRN) and PBKR03 for Krabbe Disease

DalCor Pharmaceuticals today announced the initiation of dal-COVID, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19.